INCHEON, South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with ...

In this free webinar, learn why antibody-drug conjugate (ADC) programs benefit from a "fail faster" approach to reduce late-stage attrition and accelerate development. Attendees will gain insight into ...

Samsung Biologics signed a partnership deal with LegoChem Biosciences focused on the development and production of antibody-drug conjugates (ADCs). Although financial details of the deal weren’t ...

Antibody-drug conjugates (ADCs) are transforming oncology with their ability to deliver potent cytotoxic agents directly to tumor cells, combining the targeting precision of monoclonal antibodies with ...

The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...

Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

(RTTNews) - WuXi XDC, a global leading Contract Research, Development and Manufacturing Organization dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated ...

Underpinning successful ADC development is a robust, reproducible, and scalable process development strategy. From controlling impurities and optimizing conjugation yield to streamlining unit ...

Optimizing ADC Physiochemical, Potency, and Impurity Analytical Methods to Enhance Product Understanding, Quality and Assess DARs for Regulatory Submissions The 5th ADC Analytical Development Summit ...

SUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co ...

SAN DIEGO – October 14 th, 2015 — Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services, today announced it is expanding its ...